The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer

Cancer Treatment Reviews

Volumn 36, Issue 2, 2010, Pages 131-141

  Matera, Lina ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Dendritic cells; HTERT; PAP; Prostate cancer; PSA; PSCA; PSMA; Survivin; Tumor associated antigens; Vaccine

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ACID PHOSPHATASE PROSTATE ISOENZYME DERIVATIVE; CANCER VACCINE; EPITOPE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN DERIVATIVE; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN DERIVATIVE; PROSTATE STEM CELL ANTIGEN; PROSTATE STEM CELL ANTIGEN DERIVATIVE; PROSTVAC; SURVIVIN; SURVIVIN DERIVATIVE; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE REVERSE TRANSCRIPTASE DERIVATIVE; UNCLASSIFIED DRUG; TUMOR ANTIGEN;

ADVANCED CANCER; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL MATURATION; CELL SURVIVAL; CLINICAL TRIAL; COMPUTER PROGRAM; CYTOREDUCTIVE SURGERY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG DOSE ESCALATION; ENZYME ACTIVITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; PREDICTION; PROSTATE CANCER; PROSTATECTOMY; REVIEW; CELLULAR IMMUNITY; IMMUNOLOGY; MALE; PROSTATE TUMOR; TREATMENT OUTCOME;

ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNITY, CELLULAR; MALE; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 77950620282     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2009.11.002     Document Type: Review

References (163)

1. Elkord E. Immunology and immunotherapy approaches for prostate cancer. Prostate Cancer Prostatic Dis 2007, 10:224-236.
2. Kiessling A., Fuessel S., Wehner R., Bachmann M., Wirth M.P., Rieber E.P., et al. Advances in specific immunotherapy for prostate cancer. Eur Urol 2008, 53:694-708.
3. Boon T., Van den Eynde B. Tumour immunology. Curr Opin Immunol 2003, 15:129-130.
4. Melief C.J. Cancer immunotherapy by dendritic cells. Immunity 2008, 29:372-383.
5. Berzofsky J.A., Terabe M., Oh S., Belyakov I.M., Ahlers J.D., Janik J.E., et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest 2004, 113:1515-1525.
6. Tarassoff P.C., Arlen P.M., Gulley J.L. Therapeutic vaccines for prostate cancer. Oncologist 2006, 11:451-462.
7. Marrari A., Iero M., Pilla L., Villa S., Salvioni R., Valdagni R., et al. Vaccination therapy in prostate cancer. Cancer Immunol Immunother 2007, 6:429-445.
8. Sonpavde G., Spencer D.M., Slawin K.M. Vaccine therapy for prostate cancer. Urol Oncol: Semi Original Invest 2007, 25:451-459.
9. Stevanovic S. Identification of tumour-associated T-cell epitopes for vaccine development. Nat Rev Cancer 2002, 7:514-520.
10. van der Bruggen P., Zhang Y., Chaux P., Stroobant V., Panichelli C., Schultz E.S., et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002, 188:51-64.
11. Cortez-Gonzalez X., Zanetti M. Telomerase immunity from bench to bedside: round one. J Transl Med 2007, 5:12.
12. Nagorsen D., Thiel E. HLA typing demands for peptide-based anti-cancer vaccine. Cancer Immunol Immunother 2008, 57:1903-1910.
13. Ju Z., Rudolph K.L. Telomeres and telomerase in cancer stem cells. Eur J Cancer 2006, 42:1197-1203.
14. Parmiani G., Russo V., Marrani A., Tutolo G., Casati C., Pilla L., et al. Universal and stemness-related tumor antigens: potential use in cancer immunotherapy. Clin Cancer Res 2007, 13:5675-5679.
15. Taubert H., Würl P., Greither T., Kappler M., Bache M., Bartel F., et al. Stem cell-associated genes are extremely poor prognostic factors for soft-tissue sarcoma patients. Oncogene 2007, 26:7170-7174.
16. Hiyama E., Hiyama K. Telomere and telomerase in stem cells. Br J Cancer 2007, 96:1020-1024.
17. Parker K.C., Bednarek M.A., Coligan J.E. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side chains. J Immunol 1994, 152:163-175.
18. Rammensee H., Bachmann J., Emmerich N.P., Bachor O.A., Stefanovic S. SYFPEITHI database for MHC ligands and peptide motifs. Immunogenetics 1999, 50:213-219.
19. Peters B., Sette A. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinform 2005, 31:6-132.
20. Balk S.P., Ko Y.J., Bubley G.J. Biology of prostate specific antigen. J Clin Oncol 2003, 21:383-391.
21. Watt K.W., Lee P.J., M'Timkulu T., Chan W.P., Loor R. Human prostate-specific antigen: structural and functional similarity with serine proteases. Proc Natl Acad Sci USA 1986, 83:3166-3170.
22. Li T.S., Beling C.G. Isolation and characterization of two specific antigens of human seminal plasma. Fertil Steril 1973, 24:134-144.
23. Oesterling J.E. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991, 145:907-923.
24. Sanda M.G., Smith D.C., Charles L.G., Hwang C., Pienta K.J., Schlom J., et al. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology 1999, 53:260-266.
25. Eder J.P., Kantoff P.W., Roper K., Xu G.X., Bubley G.J., Boyden J., et al. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000, 6:1632-1638.
26. Meidenbauer N., Harris D.T., Spitler L.E., Whiteside T.L. Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer. Prostate 2000, 43:88-100.
27. Gulley J.L., Arlen P.M., Bastian A., Morin S., Marte J., Beetham P., et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005, 11:3353-3362.
28. Barrou B., Benoit G., Ouldkaci M., Cussenot O., Salcedo M., Agrawal S., et al. Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol Immunother 2004, 53:453-460.
29. Heiser A., Coleman D., Dannull J., Yancey D., Maurice M.A., Lallas C.D., et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002, 109:409-417.
30. Corman J.M., Sercarz E.E., Nanda N.K. Recognition of prostatespecific antigen peptide determinants by human CD4 and CD8 T cells. Clin Exp Immunol 1998, 114:166-172.
31. Correale P., Walmsley K., Nieroda C., Zaremba S., Zhu M., Scholm J., et al. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J Natl Cancer Inst 1997, 89:293-300.
32. Xue B.H., Zhang Y., Sosman J.A., Peace D.J. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate 1997, 30:73-78.
33. Chakraborty N.G., Stevens R.L., Mehrotra S., Laska E., Taxel P., Sporn J.R., et al. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol Immunother 2003, 52:497-505.
34. Alexander R.B., Brady F., Leffell M.S., Tsai V., Celis E. Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer. Urology 1998, 51:150-157.
35. Perambakam S., Xue B.H., Sosman J.A., Peace D.J. Induction of Tc2 cells with specificity for prostate-specific antigen form patients with hormone-refractory prostate cancer. Cancer Immunol Immunother 2002, 51:263-270.
36. Waeckerle-Men Y., Uetz-von Allmen E., Fopp M., von Moos R., Böhme C., et al. Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma. Cancer Immunol Immunother 2006, 55:1524-1533.
37. Thomas-Kaskel A.K., Zeiser R., Jochim R., Robbel C., Schultze-Seemann W., Waller C.F., et al. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int J Cancer 2006, 119:2428-2434.
38. Perambakam S., Hallmeyer S., Reddy S., Mahmud N., Bressler L., DeChristopher P., et al. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer Immunol Immunother 2006, 55:1033-1042.
39. Hildenbrand B., Sauer B., Kalis O., Stoll C., Freudenberg M.A., Niedermann G., et al. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells - a pilot study. Prostate 2007, 67:500-508.
40. Kutscher W., Wolbergs H. Prostataphosphatase. Ztschr f Physiol Chem 1935, 236-237.
41. Lam K.W., Li C.Y., Yam L.T., Sun T., Lee G., Ziesmer S. Improved immunohistochemical detection of prostatic acid phosphatase by a monoclonal antibody. Prostate 1989, 15:13-21.
42. Solin T., Kontturi M., Pohlmann R., Vihko P. Gene expression and prostate specificity of human prostatic acid phosphatase (PAP): evaluation by RNA blot analysis. Biochim Biophys Acta 1990, 1048:72-77.
43. Gutman E.B., Sproul E.E., Gutman A.B. Significance of increased phosphatise activity of bone at the site of osteoblastic metastases secondary to carcinoma of the prostate gland. Am J Cancer 1936, 28:485.
44. Gutman A.B., Gutman E.B. An " acid" phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland. J Clin Invest 1938, 17:473-478.
45. Jacobs E., Haskell C. Clinical use of tumor markers in oncology. Curr Probl Cancer 1991, 15:299-360.
46. Johnson L.E., Frye T.P., Arnot A.R., Marquette C., Couture L.A., Gendron-Fitzpatrick A., et al. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine 2006, 24:293-303.
47. Fong L., Brockstedt D., Benike C., Breen J.K., Strang G., Ruegg C.L., et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 2001, 167:7150-7156.
48. McNeel D.G., Dunphy E.J., Davies J.G., Frye T.P., Johnson L.E., Staab M.J., et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009, 27:4047-4054.
49. Tao M.H., Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 1993, 362:755-758.
50. Small E.J., Fratesi P., Reese D.M., Strang G., Laus R., Peshwa M.V., et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000, 18:3894-3903.
51. Small E.J., Schellhammer P.F., Higano C.S., Redfern C.H., Nemunaitis J.J., Valone F.H., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006, 24:3089-3094.
52. Higano C.S., Schellhammer P.F., Small E.J., Burch P.A., Nemunaitis J., Yuh L., et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115:3670-3679.
53. Peshwa M.V., Shi J.D., Ruegg C., Laus R., van Schooten W.C. Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 1998, 36:129-138.
54. Israeli R.S., Powell C.T., Fair W.R., Heston W.D. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993, 53:227-230.
55. Pinto J.T., Suffoletto B.P., Berzin T.M., Qiao C.H., Lin S., Tong W.P., et al. Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996, 2:1445-1451.
56. Heston W.D. Significance of prostate-specific membrane antigen (PSMA). A neurocarboxypeptidase and membrane folate hydrolase. Urol A 1996, 35:400-407.
57. Bostwick D.G., Pacelli A., Blute M., Roche P., Murphy G.P. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998, 82:2256-2261.
58. Lapidus R.G., Tiffany C.W., Isaacs J.T., Slusher B.S. Prostate-specific membrane antigen (PSMA) enzyme activity is elevated in prostate cancer cells. Prostate 2000, 45:350-354.
59. Su S.L., Huang I.P., Fair W.R., Powell C.T., Heston W.D. Alternatively spliced variants of prostate-specific membrane antigen RNA ratio of expression as a potential measure of progression. Cancer Res 1995, 55:1441-1443.
60. Kawakami M., Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res 1997, 57:2321-2324.
61. Wright G.L., Grob B.M., Haley C., Grossman K., Newhall K., Petrylak D., et al. Upregulation of prostate-specific membrane antigen after androgen deprivation therapy. Urology 1996, 48:326-334.
62. Ross J.S., Sheehan C.E., Fisher H.A., Kaufman R.P., Kaur P., Gray K., Webb I., et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003, 9:6357-6362.
63. Mitsiades C.S., Lembessis P., Sourla A., Milathianakis C., Tsintavis A., Koutsilieris M. Molecular staging by RT-PCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer. Clin Exp Metast 2004, 21:495-505.
64. Kusumi T., Koie T., Tanaka M., Matsumoto K., Sato F., Kusumi A., et al. Immunohistochemical detection of carcinoma in radical prostatectomy specimens following hormone therapy. Pathol Int 2008, 58:687-694.
65. Cao K.Y., Mao X.P., Wang D.H., Xu L., Yuan G.Q., Dai S.Q., et al. High expression of PSM-E correlated with tumor grade in prostate cancer: a new alternatively spliced variant of prostate-specific membrane antigen. Prostate 2007, 67:1791-1800.
66. Mannweiler S., Amersdorfer P., Trajanoski S., Terrett J.A., King D., Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 2009, 15:167-172.
67. Rajasekaran S.A., Christiansen J.J., Schmid I., Oshima E., Ryazantsev S., Sakamoto K., et al. Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability. Mol Cancer Ther 2008, 7:2142-2145.
68. Yao V., Bacich D.J. Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro. Prostate 2006, 66:867-875.
69. Yao V., Parwani A., Maier C., Heston W.D., Bacich D.J. Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. Cancer Res 2008, 68:9070-9077.
70. Barwe S.P., Maul R.S., Christiansen J.J., Anilkumar G., Cooper C.R., Kohn D.B., et al. Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix. Int J Oncol 2007, 30:899-904.
71. Colombatti M., Grasso S., Porzia A., Fracasso G., Scupoli M.T., Cingarlini S., et al. The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways. PLoS ONE 2009, 4:e4608.
72. Elsässer-Beile U., Bühler P., Wolf P. Targeted therapies for prostate cancer against the prostate specific membrane antigen. Curr Drug Targets 2009, 10:118-125.
73. Silver D.A., Pellicer I., Fair W.R., Heston W.D., Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997, 3:81-85.
74. Liu H., Moy P., Kim S., Xia Y., Rajasekaran A., Navarro V., et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997, 57:3629-3634.
75. Chang S.S., O'Keefe D.S., Bacich D.J., Reuter V.E., Heston W.D., Gaudin P.B. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999, 5:2674-2681.
76. Chang S.S., Reuter V.E., Heston W.D., Bander N.H., Grauer L.S., Gaudin P.B. Five different anti-prostatespecific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999, 59:3192-3198.
77. Baccala A., Sercia L., Li J., Heston W., Zhou M. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology 2007, 70:385-390.
78. Wang K., Gao X., Pang J., Liu X., Cai Y., Zhang Y., et al. Dendritic cells transduced with a PSMA-encoding adenovirus and cocultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against prostate cancer cells. Urol Oncol 2009, 27:26-32.
79. Mincheff M., Zoubak S., Altankova I., Tchakarov S., Makogonenko Y., Botev C., et al. Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes. Cancer Gene Ther 2003, 10:907-917.
80. Lu J., Celis E. Recognition of prostate tumor cells by cytotoxic T lymphocytes specific for prostate-specific membrane antigen. Cancer Res 2002, 62:5807-5812.
81. Garetto S., Sizzano F., Brusa D., Tizzani A., Malavasi F., Matera L. Binding of prostate-specific membrane antigen to dendritic cells: a critical step in vaccine preparation. Cytotherapy 2009, 26:1-11.
82. + prostate cancer patients. Oncol Rep 2004, 12:601-607.
83. Tjoa B.A., Simmons S.J., Bowes V.A., Ragde H., Rogers M., Elgamal A., et al. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998, 36:39-44.
84. Murphy G.P., Tjoa B.A., Simmons S.J., Ragde H., Rogers M., Elgamal A., et al. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 1999, 39:54-59.
85. Murphy G.P., Tjoa B.A., Simmons S.J., Jarisch J., Bowes V.A., Ragde H., et al. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 1999, 38:73-78.
86. Murphy G.P., Tjoa B.A., Simmons S.J., Rogers M.K., Kenny G.M., Jarisch J. Higher dose and less frequent dendritic cell infusions with PSMA peptides in hormone-refractory metastatic prostate cancer patients. Prostate 2000, 43:59-62.
87. Lodge P.A., Jones L.A., Bader R.A., Murphy G.P., Salgaller M.L. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 2000, 60:829-833.
88. Fuessel S., Meye A., Schmitz M., Zastrow S., Linné C., Richter K., et al. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial. Prostate 2006, 66:811-812.
89. Knight D., Peterson A.C., Rini B.I., Harlin H., Gajewski T.F., Stadler W.M. The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer. Prostate 2009, 69:142-148.
90. Antica M., Wu L., Scollay R. Stem cell antigen 2 expression in adult and developing mice. Immunol Lett 1997, 55:47-51.
91. Tran C.P., Lin C., Yamashiro J., Reiter R.E. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res 2002, 2:113-121.
92. Bui M., Reiter R.E. Stem cell genes in androgen-independent prostate cancer. Cancer Metast Rev 1999, 17:391-399.
93. Uzgare A.R., Xu Y., Isaacs J.T. In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. J Cell Biochem 2004, 91:196-205.
94. Zhigang Z., Wenlu S. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate. Prostate 2008, 68:190-199.
95. Gu Z., Thomas G., Yamashiro J., Shintaku I.P., Dorey F., Raitano A., et al. Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 2000, 19:1288-1296.
96. Han K.R., Seligson D.B., Liu X., Horvath S., Shintaku P.I., Thomas G.V., et al. Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. J Urol 2004, 171:1117-1121.
97. Lam J.S., Yamashiro J., Shintaku I.P., Vessella R.L., Jenkins R.B., Horvath S., et al. Prostate stem cell antigen is overexpressed in prostate cancer metastases. Clin Cancer Res 2005, 11:2591-2596.
98. Kaplan-Lefko P.J., Chen T.M., Ittmann M.M., Barrios R.J., Ayala G.E., Huss W.J., et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003, 55:219-237.
99. Garcia-Hernandez Mde L., Gray A., Hubby B., Klinger O.J., Kast W.M. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 2008, 68:861-869.
100. Moore M.L., Teitell M.A., Kim Y., Watabe T., Reiter R.E., Witte O.N., et al. Deletion of PSCA increases metastasis of TRAMP-induced prostate tumors without altering primary tumor formation. Prostate 2008, 68:139-151.
101. Dannull J., Diener P.A., Prikler L., Furstenberger G., Cerny T., Schmid U., et al. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res 2000, 60:5522-5528.
102. Kiessling A., Schmitz M., Stevanovic S., Weigle B., Holig K., Fussel M., et al. Prostate stem cell antigen: identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. Int J Cancer 2002, 102:390-397.
103. + patients with hormone-refractory prostate cancer. Cancer Immunol Immunother 2004, 53:479-489.
104. Hahn W.C., Meyerson M. Telomerase activation, cellular immortalization and cancer. Ann Med 2001, 33:123-129.
105. Hiyama K., Hirai Y., Kyoizumi S., Akiyama M., Hiyama E., Piatyszek M.A., et al. Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J Immunol 1995, 155:3711-3715.
106. Weng N.P., Hathcock K.S., Hodes R.J. Regulation of telomere length and telomerase in T and B cells: a mechanism for maintaining replicative potential. Immunity 1998, 9:151-157.
107. Meyerson M., Counter C.M., Eaton E.N., Ellisen L.W., Steiner P., Caddle S.D., et al. hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 1997, 90:785-795.
108. Nakamura T.M., Morin G.B., Chapman K.B., Weinrich S.L., Andrews W.H., Lingner J., et al. Telomerase catalytic subunit homologs from fission yeast and human. Science 1997, 277:955-959.
109. Counter C.M., Meyerson M., Eaton E.N., Ellisen L.W., Caddle S.D., Haber D.A., et al. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 1998, 16:1217-1222.
110. Vaziri H., Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 1998, 8:279-282.
111. Cong Y.S., Wright W.E., Shay J.W. Human telomerase and its regulation. Microbiol Mol Biol Rev 2002, 66:407-425.
112. Hahn W.C., Stewart S.A., Brooks M.W., York S.G., Eaton E., Kurachi A., et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999, 5:1164-1170.
113. Herbert B., Pitts A.E., Baker S.I., Hamilton S.E., Wright W.E., Shay J.W., et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. Proc Natl Acad Sci USA 1999, 96:14276-14281.
114. Zhang X., Mar V., Zhou W., Harrington L., Robinson M.O. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 1999, 13:2388-2399.
115. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994, 266:2011-2015.
116. Ramakrishnan S., Eppenberger U., Mueller H., Shinkai Y., Narayanan R. Expression profile of the putative catalytic subunit of the telomerase gene. Cancer Res 1998, 58:622-625.
117. Gross D.A., Graff-Dubois S., Opolon P., Cornet S., Alves P., Bennaceur-Griscelli A., et al. High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest 2004, 113:425-433.
118. Zhang W., Kapusta L.R., Slingerland J.M., Klotz L.H. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res 1998, 58:619-621.
119. Pfitzenmaier J., Ellis W.J., Arfman E.W. Telomerase activity in disseminated prostate cancer cells. BJU Int 2006, 97:1309-1313.
120. Nair S.K., Heiser A., Boczkowski D., Majumdar A., Naoe M., Lebkowski J.S., et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000, 6:1011-1017.
121. Mennuni C., Ugel S., Mori F., Cipriani B., Iezzi M., Pannellini T., et al. Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer. Cancer Res 2008, 68:9865-9874.
122. Vonderheide R.H., Hahn W.C., Schultze J.L., Nadler L.M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999, 10:673-679.
123. Minev B., Hipp J., Firat H., Schmidt J.D., Langlade-Demoyen P., Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci USA 2000, 97:4796-4801.
124. Dupont J., Latouche J.B., Ma C., Sadelain N. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res 2005, 65:5417-5427.
125. Vonderheide R.H., Domchek S.M., Schultze J.L., George D.J., Hoar K.M., Chen D.Y., et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8 T lymphocytes. Clin Cancer Res 2004, 10:828-839.
126. Ayyoub M., Migliaccio M., Guillaume P., Lienard D., Cerottini J.C., Romero P., et al. Lack of tumor recognition by hTERT peptide 540-548-specific CD8({thorn}) T cells from melanoma patients reveals inefficient antigen processing. Eur J Immunol 2001, 31:2642-2651.
127. Purbhoo M.A., Li Y., Sutton D.H., Brewer J.E., Gostick E., Bossi G., et al. The HLA A0201-restricted hTERT540-548 peptide is not detected on tumor cells by a CTL clone or a high-affinity T-cell receptor. Mol Cancer Ther 2007, 6:2081-2091.
128. Parkhurst M.R., Riley J.P., Igarashi T., Li Y., Robbins P.F., Rosenberg S.A. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res 2004, 10:4688-4698.
129. Wenandy L., Sørensen R.B., Sengeløv L., Svane I.M., thor Straten P., Andersen M H. The immunogenicity of the hTERT540-548 peptide in cancer. Clin Cancer Res 2008, 14:4-7.
130. Vonderheide R.H., Schultze J.L., Anderson K.S., Maecker B., Butler M.O., Xia Z., et al. Equivalent induction of telomerase-specific cytotoxic T lymphocytes from tumor-bearing patients and healthy individuals. Cancer Res 2001, 61:8366-8370.
131. Filaci G., Fravega M., Setti M., Traverso P., Millo E., Fenoglio D., et al. Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer. Blood 2006, 107:1505-1512.
132. Ambrosini G., Adida C., Sirugo G., Altieri D.C. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 1998, 273:11177-11182.
133. Gianani R., Jarboe E., Orlicky D., Frost M., Bobak J., Lehner R., et al. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum Pathol 2001, 32:119-125.
134. Altieri D.C. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003, 3:46-54.
135. Islam A., Kageyama H., Takada N., Kawamoto T., Takayasu H., Isogai E., et al. High expression of survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene 2000, 19:617-623.
136. Idenoue A., Hirohashi Y., Torigoe T., Sato Y., Tamura Y., Hariu H., et al. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins. Clin Cancer Res 2005, 11:1474-1482.
137. Tran J., Rak J., Sheehan C., Saibil S.D., LaCasse E., Korneluk R.G., et al. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 1999, 264:781-788.
138. Wobser M., Keikavoussi P., Kunzmann V., Weininger M., Andersen M.H., Becker J.C. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 2006, 55:1294-1298.
139. Karam J.A., Lotan Y., Ashfaq R., Sagalowsky A.I., Shariat S.F. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology 2007, 70:482-486.
140. Zhang M., Latham D.E., Delaney M.A., Chakravarti A. Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 2005, 24:2474-2482.
141. Cho H.I., Kim E.K., Park S.Y., Lee S.K., Hong Y.K., Kim T.G. Enhanced induction of anti-tumor immunity in human and mouse by dendritic cells pulsed with recombinant TAT fused human survivin protein. Cancer Lett 2007, 258:189-198.
142. Kim C.H., Woo S.J., Park J.S., Kim H.S., Park M.Y., Park S.D., et al. Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. Immunology 2007, 122:615-622.
143. Xiang R., Mizutani N., Luo Y., Chiodoni C., Zhou H., Mizutani M., et al. A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication. Cancer Res 2005, 65:553-561.
144. Schmitz M., Diestelkoetter P., Weigle B., Schmachtenberg F., Stevanovic S., Ockert D., et al. Generation of survivin-specific CD81 T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 2000, 60:4845-4849.
145. Andersen M.H., Pedersen L.O., Becker J.C., Straten P.T. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 2000, 61:869-872.
146. Falk K., Rotzschke O., Stevanovic S., Jung G., Rammensee H.G. Allele specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 1991, 351:290-296.
147. Andersen M.H., Pedersen L.O., Capeller B., Bröcker E.B., Becker J.C., thor Straten P. Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 2001, 61:5964-5968.
148. Casati C., Dalerba P., Rivoltini L., Gallino G., Deho P., Rini F., et al. The apoptosis inhibitor protein survivin induces tumor-specific CD8 and CD4 T cells in colorectal cancer patients. Cancer Res 2003, 63:4507-4515.
149. Hirohashi Y., Torigoe T., Maeda A., Nabeta Y., Kamiguchi K., Sato T., et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 2002, 8:1731-1739.
150. Doehn C. Immunotherapy of prostate cancer. Eur Urol 2008, 53:681-683.
151. Drake C.G. Immunotherapy for prostate cancer: walk, don't run. J Clin Oncol 2009, 27:4035-4037.
152. Lake R.A., Robinson B.W. Immunotherapy and chemotherapy - a practical partnership. Nat Rev Cancer 2005, 5:397-405.
153. Kepp O., Tesniere A., Zitvogel L., Kroemer G. The immunogenicity of tumor cell death. Curr Opin Oncol 2009, 21:71-76.
154. Manfredi A.A., Capobianco A., Bianchi M.E., Rovere-Querini P. Regulation of dendritic- and T-cell fate by injury-associated endogenous signals. Crit Rev Immunol 2009, 29:69-86.
155. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-1059.
156. Brusa D., Garetto S., Chiorino G., Scatolini M., Migliore E., Camussi G., et al. Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity. Vaccine 2008, 26:6422-6432.
157. Brusa D., Migliore E., Garetto S., Simone M., Matera L. Immunogenicity of 56 degrees C and UVC-treated prostate cancer is associated with release of HSP70 and HMGB1 from necrotic cells. Prostate 2009, 69:1343-1352.
158. Arlen P.M., Gulley J.L., Parker C., Skarupa L., Pazdur M., Panicali D., et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006, 12:1260-1269.
159. Aragon-Ching J.B., Williams K.M., Gulley J.L. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci 2007, 12:4957-4971.
160. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-915.
161. Partin A.W., Mohler J.L., Piantadosi S., Brendler C.B., Sanda M.G., Walsh P.C., et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urolocy 1995, 45:831-838.
162. Elkord E., Rowbottom A.W., Kynaston H., Williams P.E. Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer. Clin Immunol 2006, 120:91-98.
163. Bronte V., Kasic T., Gri G., Gallana K., Borsellino G., Marigo I., et al. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J Exp Med 2005, 201:1257-1268.